Who can use Welireg(Belzutifan)?

Belzutifan is a novel small-molecule targeted drug developed by Merck & Co., Inc. in the United States. 

Who can use Welireg(Belzutifan)?

The drug is primarily used for the treatment of renal cell carcinoma, central nervous system hemangioblastoma, and pancreatic neuroendocrine tumors associated with Von Hippel-Lindau (VHL) disease.

Belzutifan was first approved for marketing by the U.S. FDA on August 13, 2021, and entered the Chinese market in November 2024. Currently, belzutifan has not been included in the national medical insurance coverage.